Universal Screening for Lynch Syndrome in Women With Endometrial and Non-Serous Ovarian Cancer (LS2)This study will maximize identification of women with Lynch Syndrome using an enhanced screening strategy to identify those at risk.Recruiting Principal Investigator Janice KwonBody Locations and Systems Ovarian DisordersArea VancouverAge 18-70
A Phase 1-2 Multi-Center Study Evaluating KTE-C19 in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1) (ZUMA-1)This is a single arm, open-label, multi-center, phase 1/2 study, to determine the safety and efficacy of KTE-C19, an autologous anti-CD19 chimeric antigen receptor (CAR)-positive T cell therapy, in refractory aggressive Non-Hodgkin Lymphoma (NHL). Recruiting Principal Investigator Kevin SongBody Locations and Systems Immune System and DisordersArea VancouverAge 18 and above
PC 360 SurvivorshipProstate Cancer Survivorship 360º is a collaboration-based initiative involving prostate cancer (PC) and survivorship researchers/clinicians from three Canadian prostate centers with the goal of identifying and tracking unmet supportive care needs of patients with localized PC and responding to tRecruiting Principal Investigator Larry GoldenbergBody Locations and Systems Prostate CancerArea VancouverAge 18 and above
Ibrutinib in Combination With Corticosteroids Versus Placebo in Combination With Corticosteroids in Subjects With New Onset Chronic Graft Versus Host…To evaluate the safety and efficacy of ibrutinib in combination with prednisone in subjects with newly diagnosed moderate to severe cGVHD. Recruiting Principal Investigator Raewyn BroadyBody Locations and Systems Leukemia, BloodArea VancouverAge 12 and above
Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic…To evaluate the safety and efficacy of ruxolitinib compared to Best Available Therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogeneic stem cell transplantation. Recruiting Principal Investigator Raewyn BroadyBody Locations and Systems LeukemiaArea VancouverAge 12 and above
A Drug Study in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)The purpose of this study is to assess the efficacy of ruxolitinib against best available therapy in participants with steroid-refractory chronic graft-versus-host disease (SR cGvHD). Recruiting Principal Investigator Raewyn BroadyBody Locations and Systems LeukemiaArea VancouverAge 12 and above
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic LeukemiaThe purpose of this study is to determine whether combination chemotherapy is more effective with or without blinatumomab in treating newly diagnosed acute lymphoblastic leukemia. Recruiting Principal Investigator Yasser Abou MouradBody Locations and Systems LeukemiaArea VancouverAge 30-70
Lymphoid Cancers Families StudyLymphocyte cancers are the fourth most common cancer in both men and women. Research into the genetics and environmental factors contributing to lymphoid cancers is an important step to prevent and/or control these cancers. Multiple diagnoses of lymphoid cancer within the same family may indicaRecruiting Principal Investigator Angela Brooks-WilsonArea Vancouver
A Study Evaluating the Efficacy of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large…The purpose of this study is to evaluate whether axicabtagene ciloleucel therapy improves the clinical outcome compared with standard of care second-line therapy in patients with relapsed/refractory Diffuse Large B Cell Lymphoma. Recruiting Principal Investigator Kevin SongBody Locations and Systems BloodArea VancouverAge 18 and above
QUEST: QUadrivalent Hpv vaccine Evaluation STudyQUEST (Quadrivalent HPV Vaccine Evaluation Study) is a Canada-wide study designed to evaluate whether 2 doses of the HPV vaccine are just as effective as 3 doses at preventing Human Papillomavirus (HPV) infection and cervical cancer. Recruiting Principal Investigator Simon DobsonBody Locations and Systems Sexually Transmitted Diseases, Cervical CancerArea VancouverAge 12-17
Selinexor and Backbone Treatments of Multiple Myeloma Patients (STOMP)This study will independently assess the efficacy and safety of two combination therapies for the treatment of patients with relapsed/refractory multiple myeloma (RR MM): selinexor + dexamethasone + pomalidomide (SdP) and selinexor + dexamethasone + bortezomib (SdB). Recruiting Principal Investigator Heather J. SutherlandBody Locations and Systems BloodArea VancouverAge 18 and above
A Pilot Study Investigating Apixaban and Dexamethasone InterAction in Multiple Myeloma (ADAM)This pilot study will investigate the impact of dexamethasone (DEX) on anti-Xa levels in participants taking apixaban 2.5 mg twice a day by mouth (PO BID).Recruiting Principal Investigator Agnes LeeBody Locations and Systems BloodArea VancouverAge 19 and above
A Study Investigating the Predictive Value of Philadelphia Positive Stem Cell Properties in Newly Diagnosed Patients With Chronic Myeloid Leukemia…Imatinib (IM) is first-line treatment for patients with newly diagnosed CML in chronic phase. The drug is associated with high rates of cytogenetic responses with minimal toxicity in approximately 80% of patients.Recruiting Principal Investigator Donna ForrestBody Locations and Systems LeukemiaArea VancouverAge 18 and above
Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma (BOSTONThis Phase 3, 2-arm, randomized, active comparator-controlled, open-label, multicenter study will compare the efficacy and health-related quality of life (HR-QoL) and assess the safety of selinexor plus bortezomib (Velcade® or generic equivalent) plus low-dose dexamethasone (SVd) versus bortezomiRecruiting Principal Investigator Heather J. SutherlandBody Locations and Systems BloodArea VancouverAge 18 years and above
Treatment-free Remission Accomplished With Dasatinib in Patients With CML (TRAD)The purpose of this study is to find out how to increase the potential for achieving an "operational cure" from chronic myeloid leukemia. An "operational cure" is a state in which a person does not require further treatment, although there may be some remaining cancer cells.Recruiting Principal Investigator Donna ForrestBody Locations and Systems LeukemiaArea VancouverAge 18 and above
Subcutaneous vs. intravenous administration of a drug in subjects with multiple myelomaThe purpose of this study is to show that subcutaneous (SC) administration of daratumumab co-formulated with recombinant human hyaluronidase PH20 (Dara SC) is non-inferior to intravenous (IV) administration of daratumumab (Dara IV) in terms of the overall response rate (ORR) and maximum trough coRecruiting Principal Investigator Heather J. SutherlandArea VancouverAge 18 and above
A Phase 3 Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects…The purpose of this study to determine if the addition of daratumumab to bortezomib + lenalidomide + dexamethasone (VRd) will improve overall minimal residual disease (MRD) negativity rate compared with VRd alone. Recruiting Principal Investigator Heather J. SutherlandArea VancouverAge 18 and above
A Study of SLC-0111 and Gemcitabine for Metastatic Pancreatic Ductal Cancer in Subjects Positive for CAIX (SLC-0111-17-01)The purpose of this study is to identify the safety, tolerability and maximum-tolerated-dose of the oral formulation of SLC-0111 in combination with IV gemcitabine in those with metastatic pancreatic ductal cancer. Recruiting Principal Investigator Daniel RenoufBody Locations and Systems Pancreatic CancerArea VancouverAge 18 and above
A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular… The purpose of this study is to evaluate the efficacy and safety of atezolizumab in combination with bevacizumab compared with sorafenib in participants with locally advanced or metastatic Hepatocellular Carcinoma (HCC) who have received no prior systemic treatment. Recruiting Principal Investigator Alan WeissBody Locations and Systems CancerArea VancouverAge 18 and above
Apixaban for the Prevention of Venous Thromboembolism in Cancer Patients (AVERT)Cancer patients have an increased risk of developing blood clots in the veins compared to non-cancer patients. Cancer patients who develop blood clots can lead to reduced life expectancy, delayed cancer treatment, and decreased quality of life.Recruiting Principal Investigator Agnes LeeBody Locations and Systems Blood ClotsArea VancouverAge 18 and above
International Lung Screen Trial (ILST)People who may be at increased risk of lung cancer due to age and smoking history will be invited to participate in this international study to determine the best way of using computed tomography (CT) of the chest to screen for early lung cancer.Recruiting Principal Investigator Stephen LamBody Locations and Systems Lung CancerArea VancouverAge 55-80
Testing the efficacy and safety of a drug therapy in Metastatic Non-Small Cell Lung CancerThe purpose of this study is to evaluate the efficacy and safety of pembrolizumab plus epacadostat alone or with platinum-based chemotherapy versus pembrolizumab plus platinum-based chemotherapy plus placebo as first-line therapy in participants with metastatic non-small cell lung cancer (NSCLC).Closed for Recruitment Principal Investigator Sasha SmiljanicBody Locations and Systems Lung CancerArea VancouverAge 18 and above
A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT) (HELIOS)The purpose of the study is to determine if overall mortality is affected one year after a hematopoietic stem cell transplant (HCT) in patients given a vaccine to prevent cytomegalovirus (CMV). Safety of ASP0113 in subjects undergoing allogeneic HCT will also be evaluated. Closed for Recruitment Principal Investigator Raewyn BroadyBody Locations and Systems LeukemiaArea VancouverAge 18 and above
Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia (AML)…This study will compare the overall survival (OS) between treatment groups of patients treated with vosaroxin and cytarabine versus patients treated with placebo and cytarabine. Closed for Recruitment Principal Investigator Donna E. HoggeBody Locations and Systems LeukemiaArea VancouverAge 18 and above
(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD PositiveThe primary objective of the study is to determine whether quizartinib monotherapy prolongs overall survival (OS) compared to salvage chemotherapy in subjects with FMS-like tyrosine kinase 3 - Internal Tandem Duplication (FLT3-ITD) positive AML who are refractory to or have relapsed within 6 montClosed for Recruitment Principal Investigator Donna E. HoggeBody Locations and Systems LeukemiaArea VancouverAge 18 and above
Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia…To confirm the efficacy of CPX-351 compared to 7+3 as first line therapy in elderly patients (60-75 yrs) with high risk (secondary) Acute Myeloid Leukemia. The primary efficacy endpoint will be overall survival. Closed for Recruitment Principal Investigator Donna E. HoggeBody Locations and Systems LeukemiaArea VancouverAge 60-75
S1011 Standard or Extended Pelvic Lymphadenectomy in Treating Patients Undergoing Surgery for Invasive Bladder CancerRATIONALE: Lymphadenectomy may remove tumor cells that have spread to nearby lymph nodes in patients with invasive bladder cancer. It is not yet known whether extended pelvic lymphadenectomy is more effective than standard pelvic lymphadenectomy during surgery.Closed for Recruitment Principal Investigator Peter BlackBody Locations and Systems CancerArea VancouverAge 18-120
Phase-3 Double-Blind, Placebo-Controlled Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence Myelofibrosis and RBC-Transfusion-Dependence (RESUME)The objective of this study is to determine whether pomalidomide is safe and effective in reversing red blood cell (RBC)-transfusion-dependence in persons with myeloproliferative neoplasm (MPN)-associated myelofibrosis.Closed for Recruitment Principal Investigator Thomas NevillBody Locations and Systems Bone DiseasesArea VancouverAge 18 and above
Expanded Access Program With Nivolumab to Treat Melanoma (Checkmate 168)The primary purpose of this study is to provide treatment with Nivolumab to subjects with histologically confirmed stage III (unresectable) or stage IV advanced melanoma who have progressed on or after prior treatment with an anti-CTLA4-containing therapy and for subjects with known BRAF mutationClosed for Recruitment Principal Investigator Sasha SmiljanicBody Locations and Systems MelanomaArea VancouverAge 18 and above
A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a…This two-arm, randomized, open-label, multicenter study will evaluate the efficacy and safety of Kadcyla (trastuzumab emtansine, also known as T-DM1) in combination with Perjeta (pertuzumab) versus Herceptin (trastuzumab) in combination with Perjeta and a taxane as adjuvant therapy in patients wiClosed for Recruitment Principal Investigator Sasha SmiljanicBody Locations and Systems Breast CancerArea North VancouverAge 18 and above
A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)The purpose of the study is to assess the efficacy, safety, and tolerability when combining pembrolizumab with epacadostat or placebo in subjects with unresectable or metastatic melanoma. Closed for Recruitment Principal Investigator Sasha SmiljanicBody Locations and Systems MelanomaArea North VancouverAge 18 and above
A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a…This two-arm, randomized, open-label, multicenter study will evaluate the effica cy and safety of Kadcyla (trastuzumab emtansine, also known as T-DM1) in combina tion with Perjeta (pertuzumab) versus Herceptin (trastuzumab) in combination wit h Perjeta and a taxane as adjuvant therapy in patientsClosed for Recruitment Principal Investigator Stephen ChiaBody Locations and Systems Breast CancerArea VancouverAge 18 and above
Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or…This trial will evaluate the efficacy and safety of combination of pomalidomide (POM) and low-dose dexamethasone (LD-Dex) (Cohort A) or the combination of pomalidomide (POM) , daratumumab (DARA) and low-dose dexamethasone (LD-Dex) (Cohort B) in subjects with relapsed or refractory multiple myelomClosed for Recruitment Principal Investigator Kevin SongBody Locations and Systems BloodArea VancouverAge 18 and above
Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast CancerThe purpose of this study is to determine if enzalutamide is safe and effective in the treatment of patients with advanced breast cancer that express the androgen receptor but do not express the estrogen or progesterone receptor and are not Her2 amplified. Closed for Recruitment Principal Investigator Karen A. GelmonBody Locations and Systems Breast CancerArea VancouverAge 18 and above
A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple MyelomaThe purpose of this study is to compare the effectiveness of daratumumab when combined with lenalidomide and dexamethasone (DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression-free survival in participants with relapsed or refractory multiple myeloma. Closed for Recruitment Principal Investigator Heather J. SutherlandBody Locations and Systems BloodArea VancouverAge 18 and above
A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3 (HPV-003)This is randomized, placebo controlled study to determine safety and efficacy of VGX-3100 DNA Vaccine delivered by Electroporation to adult women with biopsy-proven HPV 16 or 18 associated Cervical intraepithelial neoplasia grade 2/3 or 3. Closed for Recruitment Principal Investigator Dianne M. MillerBody Locations and Systems Sexually Transmitted Diseases, Cervical CancerArea VancouverAge 18-55
A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients…The purpose of this phase 3, randomized, double-blind, multicenter study is to compare Oral Ixazomib (MLN9708) plus Lenalidomide and Dexamethasone versus Placebo plus Lenalidomide and Dexamethasone in adult patients with relapsed and/or refractory multiple myeloma. Closed for Recruitment Principal Investigator Kevin SongBody Locations and Systems BloodArea VancouverAge 18 and above
A Study in Subjects With Relapsed and Refractory Multiple Myeloma Receiving Carfilzomib in Combination With Dexamethasone, Comparing Once-weekly Versus Twice-weekly…The purpose of the study is to compare once-weekly carfilzomib dosing in combination with dexamethasone to twice-weekly carfilzomib dosing in combination with dexamethasone in subjects with relapsed and refractory multiple myeloma, previously treated with bortezomib and an immunomodulatory agent Closed for Recruitment Principal Investigator Kevin SongBody Locations and Systems BloodArea VancouverAge 18 and above
A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Subjects With Newly Diagnosed Multiple MyelomaThis is a multicenter, open-label, Phase 1/2 study to determine the recommended dose and regimen of durvalumab in combination with lenalidomide (LEN) with and without dexamethasone (dex) in subjects with Newly diagnosed multiple myeloma (NDMM).Closed for Recruitment Principal Investigator Kevin SongBody Locations and Systems BloodArea Vancouver
An Investigational Immuno-therapy Study of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma (CheckMate 602)The purpose of this study is to evaluate the safety and effectiveness of several combination therapies for Multiple Myeloma. Upon entry into the study, patients will be randomized (assigned by chance) to receive either:Closed for Recruitment Principal Investigator Kevin SongBody Locations and Systems Blood, Heart and CirculationArea VancouverAge 18 and above
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma Who Have Been Treated With One Prior Therapy (METIV-HCC)The purpose of this study is to determine if tivantinib (ARQ 197) is effective in treating patients with MET diagnostic-high hepatocellular carcinoma (liver cancer) who have already been treated once with another therapy. Closed for Recruitment Principal Investigator Alan WeissBody Locations and Systems Cancer, Hepatitis CArea VancouverAge 18 and above
A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Patients…This is a 3-arm, randomized, open-label, parallel group study of TAK-385, together with a leuprorelin observational cohort, in patients with prostate cancer who require first-line androgen deprivation therapy (ADT). Closed for Recruitment Principal Investigator Kim Nguyen ChiBody Locations and Systems Prostate CancerArea VancouverAge 18 and above
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer (STOP-HCC)The safety and effectiveness of TheraSphere will be evaluated in patients with unresectable hepatocellular carcinoma in whom treatment with standard-of-care sorafenib is planned. All patients receive the standard-of-care sorafenib with or without the addition of TheraSphere. Closed for Recruitment Principal Investigator David Ming-Teh LiuBody Locations and Systems LiverArea VancouverAge 18 and above
Study of Pembrolizumab (MK-3475) as Monotherapy in Adults With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224)This is a efficacy and safety study of pembrolizumab (MK-3475, KEYTRUDA®) as monotherapy in participants with previously systemically treated hepatocellular carcinoma (HCC).Closed for Recruitment Principal Investigator Eric M. YoshidaBody Locations and Systems CancerArea VancouverAge 18 and above
A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants…The purpose of this study is to determine if newly diagnosed (within previous 3 months) participants with metastatic (spread of cancer cells from one part of the body to another ) hormone-naive prostate cancer (mHNPC) who have high-risk prognostic factors will benefit from the addition of abirateClosed for Recruitment Principal Investigator Kim Nguyen ChiBody Locations and Systems Prostate CancerArea VancouverAge 18 and above
An Efficacy and Safety Study of JNJ56021927 in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)The purpose of this study is to compare the radiographic progression-free survival (rPFS) of JNJ56021927 in combination with abiraterone acetate (AA) plus prednisone or prednisolone (AAP) and AAP in participants with chemotherapy-naive (participants who did not receive any chemotherapy [treatmentClosed for Recruitment Principal Investigator Martin GleaveBody Locations and Systems Prostate CancerArea VancouverAge 18 and above
